June 2013

CURRICULUM VITAE

Michael T. Bennett, MD

San Diego Digestive Disease Consultants, Inc.
Medical Associates Research Group, Inc.

Diplomate American Board of Gastroenterology, Internal Medicine
Board Certified

8008 Frost Street
Suite 200
San Diego, CA 92123
(858) 292-7527 24-Hour
(858) 292-7804 SDDD Fax

(858) 277-5678 MARG
(858) 277-2317 MARG Fax

3405 Kenyon Street
Suite 405
San Diego, CA 92110
(619) 223-5574
(619) 223-5279 Fax

E-Mail: michael.bennett@marginc.com

PREMEDICAL EDUCATION:

Hamilton College
Clinton, New York
BA Biology 1973

MEDICAL EDUCATION:

Georgetown University
Washington, DC
MD 1977

HOSPITAL TRAINING:

Straight Medical Internship Kaiser Foundation Hospital, Oakland, CA	1977-1978
Resident in Internal Medicine Kaiser Foundation Hospital, Oakland, CA	1977-1980
Fellow in Gastroenterology University of California; San Diego, CA	1981-1983

EMPLOYMENT:

Staff Physician, Kaiser Foundation Hospital, Oakland, CA	1980-1981
Part-time ER and Family Practice Physician Kaiser Foundation Hospital 4647 Zion Avenue, San Diego, CA	1981-1893
M.T. Bennett, MD, Inc. San Diego, CA	1983-Present

	San Diego Digestive Disease Consultants CEO	1987-Present
	Medical Associates Research Group, Inc. CEO	1998-Present
	San Diego Endoscopy Center 4033 Third Avenue, San Diego, CA 92103	1989-Present

POSITIONS:

Clinical Associate Professor of Medicine and Gastroenterology University of California, San Diego San Diego, CA	1983-1987
Chief, Department of Gastroenterology Sharp Memorial Hospital San Diego, CA	1986-1988
Member of Internal Medicine Supervisory Committee Sharp Cabrillo Hospital	1986-1996
Vice Chairman, Medical Staff Sharp Cabrillo Hospital San Diego, CA	1990-1993
Secretary-Treasurer of Executive Medical Board Sharp Cabrillo Hospital San Diego, CA	1993-1997
Member of Internal Medicine Supervisory Committee Sharp Memorial Hospital San Diego, CA	1987-1992
Vice Chairman, Internal Medicine Dept. Sharp Memorial Hospital San Diego, CA	1990
Chairman of Gastroenterology Sharp Community Medical Group	1995-2002

MEMBERSHIPS:

1. California Medical Association
2. San Diego County Medical Association
3. Southern California Gastroenterology Society
4. American Gastroenterology Association
5. The Obesity Society
6. San Diego Integrated NAFLD Research Consortium (SINC)

CERTIFICATION:	Diplomat, American Board of Internal Medicine	1980
	Diplomat, American Board of Gastroenterology	1984
	Good Clinical Practices Certificate NIH	2001
	Good Clinical Practices Certificate (Sponsor)	2006
	Good Clinical Practices Certificate (Sponsor)	2008
	Good Clinical Practices Certificate (Sponsor)	2009
	Good Clinical Practices Certificate (Sponsor)	2011

LICENSE: California G37728 BNDD: AB-8331186

AWARDS: New York State Regents Scholarship
National Honor Society

PUBLICATIONS:

1. Bennett et al., Diagnosis of Acute Cholecystitis by Commercially Available Radionuclide Scintigraphy with Technetium (TC PIPIDA), American Journal of Surgery, September 1982

2. Bennett, Weber, Killebrew, Primary Angiosarcoma of the Heart Detected by Technetium-labeled Erythrocyte Cardiac Imaging, Cancer, June 1982

3. Bennett et al., Collagen Production in Skin Fibroblasts in Alcoholic Patients, Gastroenterology, May 1983

4. Holt, Bennett, Chojkier, Acetaldehyde Stimulates Collagen and Noncollagen Protein Production by Human Fibroblasts, Hepatology, November 1984

5. Holt, Bennett, Chojkier, Fibronectin Production in Alcoholic Patients, Gastroenterology, May 1984

6. Scholmerich, Bennett, Johnson, Miyai, DeLuca, Hoffman, Utility of Plasma 7 Alpha Hydroxy Bile Acid Levels as Measured by Bioluminence for Detection of Methotrexate Induced Liver Injury in Patients with Psoriasis, Clin, Chem. Enzyme Comms., 1990

7. Low, Francis, Politoske, Bennett, Crohn's Disease Evaluation: Comparison of Contrast-Enhanced MR Imaging and Single-Phase Helical CT Scanning. Journal of Magnetic Resonance Imaging, 2000; 11:127-135.

8. Skikne, Punnonen, Caldron, Bennett, Ervasti, Gasior, Chamerlin, Sullivan, Bray, Southwick, Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor (sTfR) and the sTfR/log ferritin index (sTfR Index). American Journal of Hematology, 2011

9. Lembo, Schneier, Shiff, Kurtz, MacDougall, Jia, Shao, Lavins, Currie, Fitch, Jeglinski, Eng, Fox, Johnston, Two Randomized Trials of Linaclotide for Chronic Constipation. New England Journal of Medicine 2011; 365:527-36

10. Lawitz, Sullivan, Rodriguez-Torres, Enayati, Bennett et al., "A 12-Week Trial of Interferon-Free Regimen Containing ABT-450/r and ABT-267 +/- Ribavirin (RBV) in Treatment-Naïve Patients with HCV Genotype 1-3." APASL 2013, Oral Presentation 033812

11. Jacobson, Gordon, Kowdley, Yoshida, Rodriguez-Torres, Sulkowski, Shiffman, Lawitz, Everson, Bennett et al., Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. New England Journal of Medicine 2013; 368;20

CLINICAL RESEARCH

1. CEA analysis of stool for early detection of colon cancer. Principal Investigator: Howard Robin, MD, Director of Lab., Sharp Memorial Hospital; Sub-investigator: Michael Bennett, MD. 1985-1986. Hybritech.

2. H. pylori serology verses endoscopic biopsy. Principal Investigator: Lynn Lancastor, MD, Director of Microbiology, Sharp Memorial Hospital; Sub-investigator: Michael Bennett, MD. 1989-1991. Quidel.

3. Hepatitis C virus serology for PCR verses liver biopsy. Principal Investigator: Art Mendoza, MD, Director of Molecular Biology, Sharp Memorial Hospital; Sub-investigator: Michael Bennett, MD. 1994-1995. Roche.

4. Dose-response clinical trial to determine the efficacy and safety of using combination pharmaceutical therapy for patients with chronic hepatitis C who have failed previous interferon treatment. Principal Investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1997. Schering-Plough (Kern-McNeill International).

5. Clinical trial to determine the efficacy of using a proton pump inhibitor for patients with non-ulcer dyspepsia. Principal Investigator: Richard Snyder, MD; Sub-investigator, Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1997. (IBRD).

6. Dose-response, double-blind, placebo controlled study to determine the efficacy and safety of experimental antiviral drug in polyp regression in patients with sporadic adenomatous polyps of the colon. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator, Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1997. Cell Pathways (Premier Research Worldwide).

7. Clinical trial to determine the efficacy and safety of using Combination pharmaceutical therapy for patients with chronic hepatitis C who are naive to interferon treatment. Principal investigator: Douglas Politoske, MD; Sub-investigator, Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1997. Schering-Plough (Kern-McNeill International).

8. Dose response, double blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of an experimental antiviral drug for irritable bowel syndrome. Sub-investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1997. Pfizer Pharmaceuticals, Inc.

9. Dose-response, double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of experimental drug for non-ulcer dyspepsia in patients with Helicobacter

pylori. Principal Investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1998. Otsuka America Pharmaceutical, Inc.

10. Dose-response, double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of experimental drug for non-ulcer dyspepsia in patients without Helicobacter pylori. Principal Investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1998. Otsuka America Pharmaceutical, Inc.

11. Dose-response, double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of experimental drug for Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1998. Smith-Kline Beecham, Inc.

12. Dose-response, double-blind, randomized, phase II clinical trial to determine the efficacy and safety of IV and/or oral experimental drug for antibiotic resistant bacteria. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1998. Pharmacia and Upjohn (ICON).

13. Dose-response, double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of IV experimental drug for patients with steroid dependent Crohn's Disease. Principal Investigator: Jeffrey Pressman, MD; Co-investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1998. ISIS Pharmaceuticals.

14. Open label phase II clinical trial to determine the efficacy, PK and safety of experimental drug for inflammatory bowel disease. Principal Investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1998. OXIS International.

15. Double-blind, randomized, comparison controlled phase II clinical trial to determine the efficacy and safety of experimental drug for H. Pylori in patients with gastric ulcers. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 1999. Janssen Pharmaceuticals (IBAH).

16. A multi-center, double-blind, placebo controlled clinical trial to determine the efficacy and safety of an oral experimental antiviral drug for enteroviral meningitis in adults and adolescents. Principal Investigator: Jeffrey Pressman, MD, Medical Associates Research Group, Inc.; Sub-investigator: Michael Bennett, MD. 1999. ViroPharma Inc. (Scirex).

17. Double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of experimental drug for Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 1999. Glaxo-Wellcome (ICON).

18. Double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of using oral pharmaceutical therapy for patients with chronic hepatitis B. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 1999. Gilead Sciences, Inc. (Quintiles).

19. Double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of IV experimental drug for patients with steroid dependent Crohn's Disease. Principal Investigator: Jeffrey Pressman, MD; Co-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 1999. ISIS Pharmaceuticals.

20. Dose-response, clinical trial to determine the efficacy and safety of using daily high dose pharmaceutical therapy Vs TIW dosing therapy for patients with chronic hepatitis C who are naive to previous treatment. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group Inc. 1999. Amgen Pharmaceuticals.

21. Dose-response, clinical trial to determine the efficacy and safety of using daily high dose pharmaceutical therapy Vs TIW dosing therapy for patients with chronic hepatitis C who have relapsed or failed previous treatment. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group Inc. 1999. Amgen Pharmaceuticals.

22. Double-blind, placebo controlled, long term, phase II clinical trial to determine the efficacy and safety of experimental drug for Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, San Diego Digestive Disease Consultants, Inc. 1998. Smith-Kline Beecham, Inc.

23. A multi-center, double-blind, placebo controlled clinical trial to determine the efficacy and safety of an oral experimental drug for gastroparesis in adults with diabetes. Principal Investigator: Daniel Einhorn, MD; Sub-investigator, Michael Bennett, MD. 1999. Janssen Pharm.

24. Phase II open-label clinical study of the effectiveness and safety of experimental drug of patients with Barrett's esophagus dysplasia. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 1999. Cell Pathways (Premier Research Worldwide).

25. Double-blind, randomized, comparison controlled phase II clinical trial to determine the efficacy and safety of experimental drug for H. Pylori in patients without gastric ulcers. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 1999. Janssen Pharmaceuticals (IBAH).

26. A multi-center, single-blind, clinical trial to determine the efficacy and safety of a new oral delivery system for the treatment of oral candidiasis in adults, adolescents and children. Principal Investigator: Jeffrey Pressman, MD, Medical Associates Research Group, Inc.; Sub-investigator: Michael Bennett, MD. 1999. Pan American Laboratories, Inc., (Bradstreet Clinical Research).

27. Double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of experimental drug for Irritable Bowel Syndrome in males. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 1999. Glaxo-Wellcome, (ICON).

28. Double-blind, randomized, placebo controlled phase II clinical trial to determine the efficacy and safety of experimental drug for alternating Irritable Bowel Syndrome in females.
Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 1999. Glaxo-Wellcome (ICON).

29. Clinical trial to determine the safety and efficacy of stool DNA screening for colon cancer. Principal Investigator: Jeffrey H. Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2000. Exact Laboratories (MTRA).

30. A multi-center, randomized, parallel group, placebo-controlled, double-blind, phase V clinical trial to determine the efficacy and safety of experimental drug on the recurrence of neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. Principal Investigator: Jeffrey H. Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2000. Merck & Co., Inc.

31. A comparative efficacy study of experimental drug in patients with erosive esophagitis. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2000. AstraZeneca (Covance).

32. A double-blind, placebo controlled trial of experimental drug of subjects without erosive esophagitis and have symptoms of chronic gastroesophageal reflux disease (GERD). Principal Investigator: Michael Bennett, MD Medical Associates Research Group, Inc. 2000. Janssen Pharmaceuticals, (PRA International).

33. A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of experimental antiviral drug for patients with drug resistant Hepatitis B virus (HBV). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2000. Gilead Sciences, Inc. (PPD).

34. A phase II safety and efficacy trial of experimental drug for ulcerative colitis. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2000. InKine Pharmaceuticals.

35. A placebo-controlled, double-blind, randomized trial of experimental antiviral drug for viral respiratory infection in adults. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2000. ViroPharma (PRA International).

36. A double-blind randomized trial of experimental drug for patients with hypertension. Principal Investigator: Jeffrey Pressman, MD, Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2000. Bristol-Myers Squibb.

37. A phase III, randomized, placebo controlled, double-blind study of safety and efficacy of experimental drug for the prevention of gastric ulcers associated with daily NSAID use in patients at risk. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2001. Astra-Zeneca (Parexel).

38. A phase III, randomized, double-blind study of comparative efficacy and safety of experimental drug for the healing of NSAID associated gastric ulcers when daily NSAID use is continued. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2001. Astra-Zeneca (Parexel).

39. An efficacy and safety study of experimental drug in the prevention of recurrent peptic ulcer bleeding after successful hemostasis. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2001. Wyeth-Ayerst.

40. A prospective, randomized, Multi-center, open label comparative safety study of experimental antiviral drug in patients with chronic Hepatitis C. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2001. Roche Laboratories.

41. A multi-center comparison of stool DNA screening with hemoccult test for the detection of colorectal neoplasia in average risk patients. Principal Investigator: Jeffrey H. Pressman; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2001. Exact Sciences (Parexel).

42. Clinical protocol for a randomized, double-blind, placebo-controlled study of the efficacy and safety of experimental drug in the prevention of colorectal sporadic adenomatous polyps. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2001. Pharmacia Corporation.

43. A 12-week, randomized, double-blind, active-controlled, multi-center, parallel group study to investigate the gastrointestinal safety of experimental drug in patients who have osteoarthritis of the knee or hip and are taking low-dose enteric-coated aspirin. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2001. Forest Laboratories (Kendle).

44. A 12-week, randomized, double-blind, placebo-controlled, fixed-dose, parallel group, multi-center, study of the safety and efficacy of experimental drug in female patients with constipation-predominant irritable bowel syndrome. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2002. Forest Laboratories.

45. A double-blind, placebo-controlled, randomized, multi-center study to investigate the safety and efficacy of experimental drug over 12 weeks followed by a 4-week re-randomized treatment period in diarrhea-predominant irritable bowel syndrome subjects. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2002. Solvay Pharmaceuticals, Inc. (Quintiles).

46. A Phase II, Randomized, Placebo-controlled, Double-blind, Multi-center Study of experimental drug Nasal Spray, 0.2% Solution for the Treatment of Natural Rhinovirus Infection in Adults. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2002. Agouron/ Pfizer.

47. Multi-center, Randomized, Active-controlled Comparison Study of the Incidence of Gastroduodenal Ulcers Associated with experimental drug + Low Dose ASA versus Naproxen +Low Dose ASA in Healthy Subjects. Principal Investigator: Michael Bennett MD, Medical Associates Research Group, Inc. 2002. Pharmacia Corporation (Kendle).

48. A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to assess the efficacy and safety of repeated treatment with experimental drug and placebo in female patients with irritable bowel syndrome with constipation. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2003. Novartis Pharmaceutical Corportation.

49. A Randomized, Double Blind Trial of investigational medication versus investigational medication in Adults with Compensated Chronic Hepatitis B. Principal Investigator: Michael Bennett, Medical Associates Research Group, Inc. 2003. Idenix Pharmaceuticals, Inc. (Quintiles).

50. A Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment with experimental drug for the Healing of Erosive Esophagitis in Patients with Moderate or Severe Erosive Esophagitis. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2003. AstraZeneca (ICON).

51. Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates for Once Daily Treatment with experimental drug for 6 Months in Patients Whose EE Has Been Healed. Principal Investigator: Michael Bennett, Medical Associates Research Group, Inc. 2003. AstraZeneca (ICON).

52. A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of experimental drug in Female Subjects with Severe Diarrhea-Predominant IBS Who Have Failed Conventional Therapy. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2003. GlaxoSmithKline (ICON).

53. A Phase 3, Multi-Center, Randomized, DoubleBlind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of experimental drug in the Treatment of Subjects with Active Ulcerative Colitis. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2003. Otsuka Maryland Research Institute, Inc. (ICON, SFBC).

54. A Randomized, Open-label, Multi-center, Efficacy and Safety Study Examining the Effects of Duration of Treatment and of a High Induction Dose of experimental antiviral drug in Patients with Chronic Hepatitis C who Did Not Respond to Previous Combination Therapy. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2003. Roche (Quintiles).

55. Symptom Relief in Patients Suffering From Gastroesophageal Reflux Disease Grade A to D According to Los Angeles Classification (LA) Treated with experimental drug. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2003. Wyeth Pharmaceuticals (The Covalent Group).

56. An open label, Multi-center, efficacy and safety study of experimental antiviral drug in patients with chronic HCV infection who are unable to tolerate or who do not respond to 12 weeks of previous therapy. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2003. Roche (PharmaResearch).

57. A randomized, double-blind, placebo-controlled multi-center study to assess the efficacy, safety, and tolerability of experimental drug alone and in combination with omeprazole given orally in patients suffering from symptomatic (non-erosive) gastroesophageal reflux disease (sGERD). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Novartis Pharmaceuticals (MedPace).

58. A Multi-center, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Determine the Efficacy and Safety of experimental drug Administered Once Daily to Hypercholesterolemic Subjects with Chronic, Well Compensated Liver Disease. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Bristol-Myers Squibb (PPD Development).

59. A Prospective, Randomized, Open-label Study Evaluating the Viral Kinetics & Pharmacokinetics of Pegasys® Plus Copegus® and PEG-Intron® plus Rebetol® in Interferon-naïve Patients with Chronic Hepatitis C. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Roche (Quintiles).

60. A Phase III multi-national, multi-centre, double-blind placebo-controlled parallel group, 26 week study to assess the maintenance of clinical response to humanised anti-TNF PEG conjugate sc, (dosed 4 weekly from Weeks 8 to 24), in the treatment of patients with active Crohn's disease who have responded to open induction therapy (dosed at weeks 0, 2 and 4) with experimental drug. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. CellTech (ICON).

61. A Phase 3, Multi-center, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of experimental drug Oral Tablets and 800mg BID of Asacol® in the Maintenance of Remission in Subjects with Ulcerative Colitis. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Otsuka Maryland Research Institute (Kendle).

62. A Multi-center, Randomized, Double Blind, Placebo Controlled Parallel Study to Determine the Effect of experimental drug 20 mg on LDL-C when Administered Once Daily to Subjects with Moderately Elevated Primary Hypercholesterolemia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Bristol Myers Squibb (PPD).

63. A Phase 2b, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of experimental drug in Subjects with Functional Dyspepsia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Yamanouchi Pharma, Inc. (PRA International).

64. A Randomized, Parallel Group, Open-Label, Prospective 12-week Comparative Study of the Safety and Efficacy of either experimental antiviral drug or Ribavirin when Co-administered with Pegylated Interferon alpha-2a in Patients with Genotype 1 Chronic Hepatitis C Infection and Refractory to Ribavirin Co-administered with Pegylated Interferon Treatment. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Akros Pharma, Inc. (Pharmanet).

65. A Multi-center, Randomized, Parallel-Group, Active-Controlled Double-Blind Study Conducted Under In-House Blinding Conditions to determine the Incidence of Gastroduodenal Ulcers in Patient With Osteoarthritis or Rheumatoid Arthritis After 12 Weeks of Treatment With experimental drug 21 mg Plus Low-Dose Aspirin, investigational mediation 42 mg Plus Low-Dose Aspirin, Celecoxib 400 mg Plus Low-Dose Aspirin or Low-Dose Aspirin Alone. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Merck & Co.

66. A multi-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of experimental drug in patients suffering from functional dyspepsia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Axcan Pharma (Parexel).

67. A double blind, placebo-controlled study of experimental drug maintenance intermittent therapy following acute treatment in patients with symptomatic Gastroesophageal Reflux Disease. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Eisai Janssen (PPD).

68. A multi-center open-label extension phase to study the long-term safety and efficacy of investigational drug in patients suffering from functional dyspepsia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2004. Axcan Pharma (Parexel).

69. Multi-center, Randomized, Active-controlled Comparison Study of the Incidence of Gastroduodenal Ulcers Associated with experimental drug + Low Dose ASA versus Naproxen + Low Dose ASA in Healthy Subjects (50-75 years of age). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Pfizer (BCCI).

70. A Randomized, Open-Label Study to Evaluate the Safety and Dose Response of an experimental drug in Combination Therapy for the Eradication of H. pylori Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. ActivBiotics (International Healthcare).

71. A Phase 2B Study of experimental antiviral drug in Combination with Pegylated Interferon Alfa-2A (Pegasys) and Ribavirin in Subjects with Chronic Genotype I Hepatitis C Non-Responsive to Prior Therapy with Pegylated Interferon Alfa and Ribavirin. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Vertex Pharmaceuticals (Covance).

72. A Phase III multi-national, multi-centre, open label, 104 week safety study to assess the safety of chronic therapy with the humanised anti-TNF PEG conjugate of experimental drug 400 mg sc, in the treatment of patients with active Crohn's disease who have previously completed studies with the experimental antiviral drug. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. CellTech (ICON).

73. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of a Human Anti-TNF Monoclonal Antibody for the Induction of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease who Have Lost Response of are Intolerant to Infliximab. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Abbott Laboratories (Kendle).

74. A Multi-center, Open Label Study of a Human Anti-TNF Monoclonal Antibody to Evaluate the Long-term Safety and Tolerability of Repeated Administration of experimental drug in Subjects with Crohn's Disease. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005 Abbott Laboratories (Kendle).

75. Randomized, Double-Blind, Double-Dummy, Placebo-Controlled 26-week Dose Response study of experimental drug with Active Comparator in Subjects with Type 2 Diabetes. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Sankyo Pharma Development (Medpace).

76. A Randomized, Double-Blind, Controlled Evaluation of experimental antiviral drug for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Gilead Sciences, Inc.

77. A Randomized, Double-Blind, Controlled Evaluation of experimental antiviral drug for the Treatment of HbeAg Positive Chronic Hepatitis B. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Gilead Sciences, Inc.

78. A 12-Week, Multi-center, Double-Blind, Randomized, Efficacy and Safety Study of experimental drug for the Treatment of Constipation-Predominant Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Sucampo Pharmaceuticals (PRA International).

79. A Double-Blind Randomized Study to Evaluate the Efficacy and Safety of experimental drug vs. Placebo in Subjects with Primary Hypercholesteremia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Takeda Global Research and Development, Inc. (PPD).

80. An Open-Label Extension Study to Evaluate the Safety and Tolerability of experimental drug in Subjects with Hypercholesterolemia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Takeda Global Research and Development, Inc.(PPD).

81. A Randomized, Double-blind, Placebo-controlled Clinical Study of the experimental drug, for the Induction of Clinical Response in Patients with Crohn's Disease. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Synta Pharmaceutical Corp. (PPD).

82. Comparison of experimental antiviral drug to Pegasys plus ribavirin in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Schering-Plough Research Institute.

83. Determination of the Minimal Clinically Important Difference (MCID) of the patient-orientated self assessment scale ReQuest™ in patients suffering from endoscopically confirmed gastroesophageal reflux disease (GERD), Grade A-D according to Los Angeles classification treated experimental drug or placebo o.d. over one week. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. ALTANA Pharma AG.

84. A Phase 3 Study to Evaluate the Efficacy and Safety of experimental drug Compared to Placebo on Symptom Relief in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005 TAP Pharmaceutical Products, Inc.

85. A Phase 3 Study to Evaluate the Efficacy and Safety of experimental drug (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. TAP Pharmaceutical Products, Inc.

86. A Phase 3 Study to Evaluate the Safety and Efficacy of experimental drug Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. TAP Pharmaceutical Products, Inc.

87. A Phase 3, Open-Label Study to Assess the Long-Term Safety of experimental antiviral drug . Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. TAP Pharmaceutical Products, Inc.

88. A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of experimental drug in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Alizyme Therapeutics Limited (Quintiles).

89. A Phase III, Multi-center, Open Label, Extension Study to Evaluate the Long-Term Safety of experimental drug Once Daily in Women with Constipation-Predominant Irritable Bowel

Syndrome (c-IBS). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2005. Alizyme Therapeutics Limited (Quintiles).

90. A Double-blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of experimental drug and Simvastatin Alone and in Combination in Subjects with Hypercholesterolemia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Takeda Global Research & Development Center, Inc. (MDS).

91. A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Different Doses of experimental drug Administered BID For Either Two or Four Weeks in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Salix Pharmaceuticals, Inc. (Kendle).

92. A Phase 2a, Randomized, Double-Blind, Placebo Controlled Dose Ranging, Multi-Center Study to Determine the Safety, Tolerance, and Efficacy of experimental drug in Celiac Disease Subjects during Gluten Challenge. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Alba Therapeutics.

93. Access® Immunoassay Systems Soluble Transferrin Receptor (sTfR) Assay Clinical Utility and Method Comparison. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Beckman Coulter Inc.

94. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Range-Finding, Parallel-Group Phase 2 Trial of experimental drug Administered to Patients with Chronic Constipation. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Microbia (ICON).

95. A Multi-center, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Flexible-Dose Study to Assess the Efficacy and Safety of experimental drug in Men with Erectile Dysfunction (ED) who do not Self Identify. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Pfizer (PPD).

96. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of experimental drug for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS) in Females. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Trine (ICON).

97. A Randomized, double-blind, parallel-group study of cardiovascular safety in OA or RA patients with or at high risk for cardiovascular disease comparing celecoxib with naproxen and ibuprofen. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Cleveland Clinic. Pfizer (Quintiles).

98. A Phase-2, Randomized, Open-Label Study of the Safety, Antiviral Activity, and Pharmacokinetics of experimental antiviral drug Administered in Combination with Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol in Subjects with Hepatitis C Virus Genotype 1 Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Wyeth Research (ICON).

99. A World-wide, Multi-Center, Double-Blind, Parallel Study to Evaluate the Tolerability of experimental drug versus Niacin Extended Release. Principal Investigator: Jeffrey Pressman,

MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Merck.

100. A Multi-Center Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of experimental drug and Simvastatin Combination Therapy to experimental drug and Simvastatin Monotherapy in Subjects with Mixed Dyslipidemia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Abbott Laboratories (Covance).

101. A Long-Term, Open-Label, Safety Extension Study of the Combination of experimental drug and Statin Therapy for Subjects with Mixed Dyslipidemia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2006. Abbott Laboratories (Covance).

102. A Multi-center, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of experimental drug given twice daily for 4 weeks for the Relief of Irritable Bowel Syndrome (IBS) pain. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Allergan.

103. Multi-center, Randomized, Double-Blind Study, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of experimental drug Versus Atorvastatin in Patients with Mixed Hyperlipidemia. Principal Investigator: Jeffrey Pressman, MD; Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Merck.

104. A Phase-3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of experimental antiviral drug in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Human Genome Sciences, Inc. (Duke Clinical Research Institute).

105. A 6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either experimental drug or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. POZEN Pharmaceutical, Inc. (Premier Research).

106. A 6-Month, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study to Evaluate the Incidence of Gastric Ulcers with experimental drug versus diclofenac/misoprostol in Subjects Who Are at High Risk for Developing NSAID-associated Ulcers. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. POZEN Pharmaceutical, Inc. (Premier Research).

107. A 12-Month, Phase 3, Open-Label, Multi-center Study to Evaluate the Long-term Safety of experimental a drug in Subjects Who Are at Risk for Developing NSAID-associated Ulcers. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. POZEN Pharmaceutical, Inc. (Premier Research).

108. A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of experimental drug in Female Outpatients with Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Pharmos Corporation (ICON).

109. A Multi-center, Randomized, Double-Blind, Active-Control, 96-Week, Phase III Trial of the Efficacy and Safety of experimental antiviral drug Compared with Adefovir in Nucleoside

Treatment-Naïve Patients with HBeAg Positive Chronic Hepatitis due to Hepatitis B virus. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Pharmasset, Inc. (PPD).

110. A Multi-center, Randomized, Double-Blind, Active-Control, 96-Week, Phase III Trial of the Efficacy and Safety of experimental antiviral drug Compared with Adefovir in Nucleoside Treatment-Naïve Patients with HBeAg Negative Chronic Hepatitis due to Hepatitis B virus. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Pharmasset, Inc. (PPD).

111. A Multi-center, Investigator-blinded, Randomized, 12-Month, Parallel-group, Non-inferiority Study to Compare the Efficacy of experimental drug Therapy Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis. Principal Investigator: Jeffrey Pressman, MD, Sub-investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Procter and Gamble Company(UBS).

112. A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of experimental drug in the Morning vs. experimental drug in the Evening vs. experimental drug Twice Daily vs. Placebo in Subjects with Hypercholesterolemia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Takeda Global Research and Development Center, Inc. (PPD).

113. A Randomized, Multi-center, Double-Blind, Placebo-Controlled, Dose-Range-Finding, Parallel-Design, Phase 2 Trial of experimental drug Administered to Patients with Irritable Bowel Syndrome with Constipation. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Microbia, Inc. (ICON).

114. A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of experimental drug in Subjects with Symptomatic Gastroesophageal Reflux Disease (GERD) Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2007. Xenoport (MDS).

115. A Phase-III, Randomized, Double-blind, Dose-Response Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of experimental drug Versus Placebo over 104 Weeks in the Prevention of Recurrence of Diverticulitis. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2008. Shire Pharmaceutical Development, Ltd. (Kendle).

116. A Double-blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of experimental drug with Valsartan in Subjects with Essential Hypertension. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2008. Takeda Global Research and Development Center, Inc.

117. A Randomized Double-Blind Parallel Study of experimental drug versus experimental drug 40 mg for Healing and Symptomatic Relief of Erosive Gastroesophageal Reflux Disease (GERD). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2008. Eisai Medical Research Inc. and Johnson and Johnson Pharmaceutical Research & Development, LLC (PPD).

118. A Randomized Double-Blind Parallel Study of experimental drug 50 mg vs. experimental drug 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal

Reflux Disease (GERD). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2008. Eisai Medical Research Inc. and Johnson and Johnson Pharmaceutical Research & Development, LLC (PPD).

119. A Randomized Double-Blind Parallel Study of experimental drug 50 mg versus experimental drug 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD). Principal Investigator: Michael Bennett, MD. Medical Associates Research Group, Inc. 2008. Eisai Medical Research Inc. and Johnson and Johnson Pharmaceutical Research & Development, LLC (PPD).

120. A Phase 3 Study of 2 Dose Regimens of experimental antiviral drug in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype I Chronic Hepatitis C. Principal Investigator: Michael Bennett, MD, Medical Associate Research Group, Inc. 2008. Vertex (Parexel).

121. A Phase 3 Safety and Efficacy Study of experimental antiviral drug in Subjects with Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment with Peginterferon/Ribavirin. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2008. Schering-Plough.

122. A Phase 3 Safety and Efficacy Study of experimental antiviral drug in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2008. Schering-Plough.

123. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of experimental drug administered orally for 12 weeks Followed by a 4-Week Randomized Withdrawal Period in Patients with Chronic Constipation. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Ironwood Pharmaceuticals (ICON).

124. A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving experimental antiviral drug , Peginterferon Alfa2a and Ribavirin. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Vertex (ICON).

125. An International, Multi Center, Randomized, Parallel Group, Prospective, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal adenomas. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Colotech (PRS Clinical).

126. An Open-label, Long-term Safety Study of oral experimental drug Administered to Patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Ironwood Pharmaceuticals (ICON).

127. A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered experimental drug in Subjects with Non-Constipating Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Lexicon Pharmaceuticals, Inc.

128. An 8-Week Randomized, Double-Blind, Parallel Group, Multi-Center, Forced Titration Study to Evaluate the Efficacy and Safety of experimental drug plus HCTZ versus experimental antiviral drug monotherapy in Metabolic Syndrome Patients with Stage 2 Hypertension. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Novartis.

129. A Single-Arm Study to Provide experimental antiviral drug Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough experimental antiviral drug Studies. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Schering-Plough.

130. A Phase 3 Safety and Efficacy Study of experimental antiviral drug in Combination with Peginterferon Alfa-2a and Ribavirin in Subjects with Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment with Peginterferon/Ribavirin. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Schering-Plough.

131. Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Centre Study to Investigate the Efficacy, Safety, and Tolerability of the experimental drug in Patients With Gastroesophageal Reflux Disease (GERD) Who Are Partial Responders to Proton Pump Inhibitor (PPI) Treatment. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Addex Pharma SA (SGS Life Science Services).

132. A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of experimental drug with experimental drug in Subjects with Essential Hypertension, Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Takeda Global Research and Development.

133. A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety and Tolerability of experimental drug 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Eisai Medical Research Inc. and Johnson and Johnson Pharmaceutical Research Inc. and Johnson and Johnson Pharmaceutical Research & Development, LLC (PPD).

134. An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of experimental drug to Simvastatin in Subjects with Hypercholesterolemia. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Abbott Laboratories (Paragon Biomedical).

135. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of experimental drug in Subjects with Generalized Erectile Dysfunction. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Vivus, Inc. (Quintiles).

136. A Phase 2B, Partially-Blinded, Randomized Study in Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses Of LoctEron™ Plus Ribavirin Given Bi-weekly In Comparison With PEG-Intron™ Plus Ribavirin Given Weekly. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Biolex Therapeutics, Inc. (SGS Life Sciences).

137. A Trial of experimental antiviral drug in Interferon-Naïve Hepatitis C Patients. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Conatus Pharmaceuticals, Inc.

138. A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of experimental antiviral drug in Adults with Chronic Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Gilead Sciences, Inc., Inc. (PRA International).

139. Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of experimental antiviral drug in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. GlaxoSmithKline.

140. Collection of Blood Samples for the Discovery of Biomarkers Associated with Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Prometheus Therapeutics and Diagnostics.

141. A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor experimental antiviral drug in Combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. F. Hoffmann-La Roche, Ltd.

142. A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the experimental antiviral drug Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Takeda Global Research & Development Center, Inc.

143. A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of experimental drug in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2009. Takeda Global Research & Development Center, Inc.

144. A Double-Blind, Double-Dummy, Randomized, Active-Comparitor, Non-Inferiority Study of experimental drug versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2010. Logical Therapeutics, Inc. (PRA International).

145. A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of experimental drug in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2010. Tioga Pharmaceuticals, Inc. (RTI).

146. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of experimental antiviral drug plus pegylated interferon alfa-2A and Ribavirin in Treatment Naïve HCV Genotype 1 Infected Subjects. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2010. Pfizer, Inc.

147. Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which experimental drug or experimental drug was Administered for the Treatment of Chronic Hepatitis C. Principal

Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2010. Schering Plough.

148. A Phase II double-blind, placebo-controlled study of two doses of experimental drug in patients with NASH. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2010. Mochida Pharmaceutical Co. (MedPace).

149. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With experimental antiviral drug , experimental antiviral drug , Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2010. Gilead Sciences, Inc. (PRA International).

150. A Phase 2b, Randomized, Double-Blind, Placebo Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of experimental antiviral drug , Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without experimental antiviral drug Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2010. Gilead Sciences, Inc. (PRA International).

151. A Randomized, Open-Label, Phase 3 Study of experimental antiviral drug Administered Twice Daily or Every 8 Hours in Combination with Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Tibotec BVBA.

152. A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without experimental drug in HCV Null-Responders. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Conatus Pharmaceuticals, Inc.

153. Procurement of Blood Samples from IBD, GI Controls and Healthy Volunteer Subjects for Use in the Development of Gastrointestinal Disease Tests. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Prometheus Laboratories.

154. A Randomized, Open-Label, Multi-Center Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of experimental antiviral drug and/or experimental antiviral drug with and without Ribavirin (RBV) for 8, 12 or 24 weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Abbott Laboratories.

155. An Open-Label, Sequential Arm, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of experimental antiviral drug with experimental antiviral drug Dosed in Combination with experimental antiviral drug with and without Ribavirin (RBV) in Treatment-Naïve Subjects with Genotype 1, 2, or 3 Chronic Hepatitis C Virus (HCV) Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Abbott Laboratories.

156. A Phase III, Randomized, Double-Blind and Placebo-Controlled Study of Once Daily experimental antiviral drug 120 mg for 24 weeks and experimental antiviral drug 240 mg for

12 weeks in Combination with Pegylated Interferon-a and Ribavirin in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Boehringer-Ingelheim.

157. Safety, Antiviral Effect and Pharmacokinetics of experimental antiviral drug in Combination with experimental antiviral drug and With or Without Ribavirin for 4, 16, 24, 28, or 40 weeks in Patients with Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Boehringer-Ingelheim.

158. Open-Label, Single-Arm Evaluation of experimental antiviral drug in Combination with Peg-Interferon Alfa-2A and Ribavirin in Black-African Americans, Latinos, and White-Caucasians with Chronic Hepatitis C Genotype 1 Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Bristol-Myers Squibb.

159. A Phase 3 Evaluation of experimental antiviral drug Compared with experimental antiviral drug in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis-C. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Bristol-Myers Squibb.

160. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Therapy using Combinations of Oral Antivirals (experimental antiviral drug s) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PRA International).

161. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with experimental antiviral drug Alone or in Combination with Experimental Antiviral Drug with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PPD).

162. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy with experimental antiviral drugs, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PPD).

163. A Phase-2, Randomized, Double-Blind, Placebo-Controlled Study of experimental antiviral drug and Ribavirin (RBV) Compared with experimental antiviral drugs with experimental antiviral drug or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011 Gilead Sciences, Inc.(PPD).

164. A Phase-2, Randomized, Double-Blind, Placebo-Controlled Study of experimental antiviral drug s and Ribavirin; experimental antiviral drug and experimental antiviral drug; experimental antiviral drug and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Genotype 1a or 1b HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PPD).

165. A Phase 2b, Randomized, Double-Blind, Placebo Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of experimental antiviral drug , Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without experimental antiviral drug Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PRA International).

166. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals experimental antiviral drug with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PRA International).

167. A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of experimental antiviral drug When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Merck Research Laboratories.

168. A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of experimental antiviral drug in Combination with Standard of Care in Hepatitis C Genotype 1 Treatment-Naïve Patients. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Novartis.

169. A Multi-Center, Open-Label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of experimental antiviral drug in Combination with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients with Chronic HCV Infection Genotype 1, 4, 5, or 6. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Pharmasset (Quintiles).

170. An International, Multi-Center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Regimens Containing experimental antiviral drug and Ribavirin in Patients with Chronic HCV Infection, Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Pharmasset (Quintiles).

171. A Phase 3, Multi-Center, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of experimental antiviral drug and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chronic Genotype 2 or 3 HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Pharmasset (Quintiles).

172. A Randomized, 12-Week Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of experimental drug in Patients with Chronic Idiopathic Constipation. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Synergy Pharmaceuticals, Inc. (Parexel).

173. An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of experimental antiviral drug in Combination with experimental

antiviral drug with or without Ribavirin in Chronic Hepatitis C Genotype 1 Infected Prior Null Responders to Peginterferon/Ribavirin Therapy. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Tibotec BVBA.

174. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Intra-Anal Application of experimental drug as a 0.5% Ointment in Subjects with Symptomatic Internal Hemorrhoids. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Ventrus Biosciences (inVentiv).

175. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of experimental drug for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2011. Ardelyx, Inc.

176. A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection (SVR Registry). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Gilead Sciences, Inc. (PRA International).

177. A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection (Sequence Registry). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Gilead Science, Inc. (PRA International).

178. A Phase 3 Evaluation of experimental antiviral drug compared with experimental drug in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis-C. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Bristol-Myers Squibb.

179. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of experimental antiviral drug + Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 or 3 HCV Infection who are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Gilead Sciences, Inc. (PRA International).

180. Safety, Antiviral Effect and Pharmacokinetics of experimental antiviral drug in Combination with experimental antiviral drug and with or without Ribavirin for 4, 16, 24, 28, or 40 Weeks in Patients with Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Boehringer-Ingelheim.

181. A Phase 3, Multicenter, Randomized, Double-Blind, Study to Investigate the Efficacy and Safety of experimental antiviral drug + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Gilead Sciences, Inc. (PRA International).

182. An Open-Label Study of experimental antiviral drug + Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection who Participated in Prior Studies Evaluating experimental antiviral drug . Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Gilead Sciences, Inc. (PRA International).

183. A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of experimental antiviral drug with Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1, 4, 5, or 6 HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Gilead Sciences, Inc. (PRA International).

184. A Multicenter, Randomized, Open-Label, Phase 2b Study to Evaluate the Efficacy and Safety of Two Regimens of All-oral Triple Therapy (experimental antiviral drug in Combination With Telaprevir [Incivek™] and Ribavirin [Copegus ®] in Treatment-Naïve Subjects With Genotype 1a Chronic Hepatitis C. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Vertex (Quintiles).

185. A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of experimental antiviral drug Fixed-Dose Combination + Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Gilead Sciences, Inc. (PRA International).

186. A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of experimental antiviral drug / experimental antiviral drug/ experimental antiviral drug and experimental antiviral drug Co-administered with Ribavirin (RBV) in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Abbott Laboratories.

187. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of experimental antiviral drug /experimental drug/ experimental antiviral drug and experimental antiviral drug Co-administered with Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Abbott Laboratories.

188. A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without experimental drug, Compared to Peginterferon Alfa-2a, Each in Combination with Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Bristol-Myers Squibb.

189. A Phase 3, Multicenter, Randomized, Open Label Study to Investigate the Efficacy and Safety of Sofosbuvir/ experimental antiviral drug Fixed-Dose Combination + Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Gilead Sciences, Inc. (PRA International).

190. Open-Label, Multiple-Dose, Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Co-administration of experimental antiviral drug, experimental antiviral drug, and experimental antiviral drug When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected with Hepatitis C Virus Genotype 1. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Bristol-Myers Squibb

191. An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced

Virologic Failure in a Previous Abbott DAA Combination Study. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Abbott Laboratories.

192. A Study to Assess Repeat Treatment Efficacy and Safety of experimental drug TID in Subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Salix Pharmaceuticals.

193. A Follow-up Study to Assess Resistance and Durability of Response to Abbott Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or Phase 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2012. Abbott Laboratories.

194. A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV). Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2013. AbbVie.

195. A Long-Term Follow-up Study of Subjects Who Participated in A Clinical Trial in Which BMS-650032 and/or BMS 790052 Was Administered for the Treatment of Chronic Hepatitis C. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2013. Bristol-Myers Squibb.

196. A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combination with Simeprevir and Ribavirin for 12 Weeks in Subjects with Chronic Hepatitis C Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2013. Idenix Pharmaceuticals (Quintiles).

197. A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2013. Gilead Sciences, Inc. (PRA International).

198. A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2013. Gilead Sciences, Inc. (Quintiles).

199. A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects with Chronic HCV Infection. Principal Investigator: Michael Bennett, MD, Medical Associates Research Group, Inc. 2013. Gilead Sciences, Inc. (Quintiles).